Scientists discovered that low doses of THC as part of a longer-term treatment plan have an anti-aging effect and may reverse ...

Pacylex was recognized as BioAlberta's 2024 Company of the Year. The award acknowledges a company that has shown significant achievement within the marketplace and Alberta's business community through ...

Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for ...

Discover how advances from various biotechs are bridging treatment gaps in menopause care, offering hope for managing ...

mTOR and tyrosine kinase inhibitors may play an increasing role in the management of well-differentiated neuroendocrine tumors in the future. Peptide receptor radiotherapy is a new treatment ...

They investigated the mammalian target of rapamycin (mTOR) signaling induction by TCR ... sodium-chloride concentrations can convert T cell receptor engagement in cytotoxic T lymphocytes into ...

Colony-stimulating factor 1 receptor (CSF1R)–dependent monocytes ... or cyclosporine), or a mammalian target of rapamycin (mTOR) inhibitor (sirolimus or everolimus) that the patient was taking ...

In a recent study, researchers used high-throughput drug screening to identify potential therapeutic targets and novel ...

The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway ... endothelial growth factor receptor 3. The company was formerly ...

Compared to placebo (dummy medicine), tolvaptan (a class of medicine known as vasopressin 2 receptor antagonists) probably preserves kidney function and slows the increase in total kidney volume; ...

Odyssey Therapeutics announced the formation of its Scientific Advisory Board, which includes experts in immunology and therapeutic development.